Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment

CNS Neuroscience and Therapeutics

Volumn 23, Issue 1, 2017, Pages 5-22

  Golpich, Mojtaba ^a   Amini, Elham ^a   Mohamed, Zahurin ^b   Azman Ali, Raymond ^a   Mohamed Ibrahim, Norlinah ^a   Ahmadiani, Abolhassan ^c  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Mitochondrial Biogenesis; Mitochondrial complexes; Mitochondrial Dysfunction; Neurodegenerative Diseases; Pathogenesis; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR; UBIQUINOL CYTOCHROME C REDUCTASE; HISTOCOMPATIBILITY ANTIGEN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL FUNCTION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; COMPLICATION; GENETICS; METABOLISM; MITOCHONDRIAL DISEASES; ORGANELLE BIOGENESIS;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS; HUMANS; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; ORGANELLE BIOGENESIS;

EID: 85006021086     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12655     Document Type: Review

References (217)

1. Filosto M, Scarpelli M, Cotelli MS, et al. The role of mitochondria in neurodegenerative diseases. J Neurol 2011;258:1763–1774.
2. Verdin E, Hirschey MD, Finley LWS, Haigis MC. Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. Trends Biochem Sci 2010;35:669–675.
3. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787–795.
4. Golpich M, Amini E, Hemmati F, et al. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. Pharmacol Res 2015;97:16–26.
5. Bernier M, Paul RK, Martin-Montalvo A, et al. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem 2011;286:19270–19279.
6. Okamoto K, Kondo-Okamoto N. Mitochondria and autophagy: Critical interplay between the two homeostats. Biochim Biophys Acta 2012;1820:595–600.
7. Piantadosi CA, Suliman HB. Redox regulation of mitochondrial biogenesis. Free Radic Biol Med 2012;53:2043–2053.
8. Hiona A, Sanz A, Kujoth GC, et al. Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PLoS One 2010;5:e11468, doi: 10.1371/journal.pone.0011468.
9. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010;9:829–840.
10. Chaturvedi RK, Beal MF. Mitochondrial diseases of the brain. Free Radic Biol Med 2013;63:1–29.
11. Yao J, Irwin RW, Zhao LQ, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:14670–14675.
12. Neustadt J, Pieczenik SR. Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 2008;52:780–788.
13. Fischer F, Hamann A, Osiewacz HD. Mitochondrial quality control: An integrated network of pathways. Trends Biochem Sci 2012;37:284–292.
14. Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008;134:112–123.
15. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol 2010;45:466–472.
16. Calkins MJ, Reddy PH. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochim Biophys Acta 2011;1812:1182–1189.
17. van der Bliek AM, Shen QF, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harbor Perspect Biol 2013;5:a011072, doi: 10.1101/cshperspect.a011072.
18. Sharma J, Johnston MV, Hossain MA. Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation. BMC Neurosci 2014;15:1–14.
19. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011;8:393–409.
20. Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 2012;120:419–429.
21. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009;132:3285–3297.
22. Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta 2012;1822:101–110.
23. Cozzolino M, Carri MT. Mitochondrial dysfunction in ALS. Prog Neurobiol 2012;97:54–66.
24. Tanaka A, Cleland MM, Xu S, et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J Cell Biol 2010;191:1367–1380.
25. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010;11:872–884.
26. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12:9–14.
27. Ding Y, Gao H, Zhao L, Wang X, Zheng M. Mitofusin 2-deficiency suppresses cell proliferation through disturbance of autophagy. PLoS One 2015;10:e0121328, doi: 10.1371/journal.pone.0121328.
28. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011;333:1109–1112.
29. Qin Z-H, Wang Y, Kegel KB, et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 2003;12:3231–3244.
30. Braun RJ. Mitochondrion-mediated cell death: Dissecting yeast apoptosis for a better understanding of neurodegeneration. Front Oncol 2012;2:1–14.
31. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2944–2950.
32. Civitarese AE, MacLean PS, Carling S, et al. Regulation of skeletal muscle oxidative capacity and insulin signaling by the mitochondrial rhomboid protease PARL. Cell Metab 2010;11:412–426.
33. Zhang D, Liu Z-X, Choi CS, et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci 2007;104:17075–17080.
34. Hirschey M, Shimazu T, Huang J-Y, Schwer B, Verdin E, editors. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2011.
35. Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005;2:e233.
36. Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007;56:1376–1381.
37. Shapovalov Y, Hoffman D, Zuch D, Bentley KLD, Elisee RA. Mitochondrial dysfunction in cancer cells due to aberrant mitochondrial replication. J Biol Chem 2011;286:22331–22338.
38. Sleigh A, Raymond-Barker P, Thackray K, et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest 2011;121:2457–2461.
39. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656–2668.
40. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 2005;39:359–407.
41. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664–671.
42. Baker BM, Haynes CM. Mitochondrial protein quality control during biogenesis and aging. Trends Biochem Sci 2011;36:254–261.
43. Onyango IG, Lu JH, Rodova M, Lezi E, Crafter AB, Swerdlow RH. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta 2010;1802:228–234.
44. Ramalingam M, Kim S-J. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. J Neural Transm 2012;119:891–910.
45. Li S-Y, Jia Y-H, Sun W-G, et al. Stabilization of mitochondrial function by tetramethylpyrazine protects against kainate-induced oxidative lesions in the rat hippocampus. Free Radic Biol Med 2010;48:597–608.
46. Muller WE, Eckert A, Kurz C, Eckert GP, Leuner K. Mitochondrial dysfunction: Common final pathway in brain aging and alzheimer's disease-therapeutic aspects. Mol Neurobiol 2010;41:159–171.
47. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007;145:1233–1248.
48. Chuang Y-C, Lin T-K, Huang H-Y, et al. Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. J Neuroinflammation 2012;9:1–18.
49. Malinska D, Kulawiak B, Kudin AP, et al. Complex III-dependent superoxide production of brain mitochondria contributes to seizure-related ROS formation. Biochim Biophys Acta 2010;1797:1163–1170.
50. Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol 2000;10:462–472.
51. Costa RO, Ferreiro E, Martins I, et al. Amyloid beta-induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiol Aging 2012;33:12.
52. Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009;30:1574–1586.
53. Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013;34:1581–1588.
54. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome proliferator-activated receptor γ induces a clearance mechanism for the amyloid-β peptide. J Neurosci 2004;24:10908–10917.
55. Folbergrová J, Ješina P, Haugvicová R, Lisý V, Houštěk J. Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem Int 2010;56:394–403.
56. Krieger C, Duchen MR. Mitochondria, Ca(2+) and neurodegenerative disease. Eur J Pharmacol 2002;447:177–188.
57. Cronin-Furman EN, Borland MK, Bergquist KE, Bennett JP Jr, Trimmer PA. Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener 2013;8:1–17.
58. Imam MU, Ismail M, Ithnin H, Tubesha Z, Omar AR. Effects of germinated brown rice and its bioactive compounds on the expression of the peroxisome proliferator-activated receptor gamma gene. Nutrients 2013;5:468–477.
59. Milakovic T, Johnson GVW. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant Huntingtin. J Biol Chem 2005;280:30773–30782.
60. Seong IS, Ivanova E, Lee JM, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005;14:2871–2880.
61. Chiang MC, Chen CM, Lee MR, et al. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 2010;19:4043–4058.
62. Cui LB, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59–69.
63. Fuenzalida K, Quintanilla R, Ramos P, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007;282:37006–37015.
64. Da Cruz S, Parone PA, Lopes VS, et al. Elevated PGC-1 alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab 2012;15:778–786.
65. Bahadorani S, Mukai ST, Rabie J, Beckman JS, Phillips JP, Hilliker AJ. Expression of zinc-deficient human superoxide dismutase in Drosophila neurons produces a locomotor defect linked to mitochondrial dysfunction. Neurobiol Aging 2013;34:2322–2330.
66. Li QA, Vande Velde C, Israelson A, et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A 2010;107:21146–21151.
67. Russell AP, Wada S, Vergani L, et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol Dis 2013;49:107–117.
68. Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008;8:1–8.
69. Coussee E, De Smet P, Bogaert E, et al. G37R SOD1 mutant alters mitochondrial complex I activity, Ca2 + uptake and ATP production. Cell Calcium 2011;49:217–225.
70. Chen HC, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009;18:R169–R176.
71. Fukui H, Moraes CT. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. Hum Mol Genet 2007;16:783–797.
72. Kilbride SM, Gluchowska SA, Telford JE, O'Sullivan C, Davey GP. High-level inhibition of mitochondrial complexes III and IV is required to increase glutamate release from the nerve terminal. Mol Neurodegener 2011;6:53.
73. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005;58:495–505.
74. Yamada ES, Respondek G, Mussner S, et al. Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of EDP-17 transgenic mice. Exp Neurol 2014;253:113–125.
75. Hoglinger GU, Carrard G, Michel PP, et al. Dysfunction of mitochondrial complex I and the proteasome: Interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 2003;86:1297–1307.
76. Menzies FM, Cookson MR, Taylor RW, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002;125:1522–1533.
77. Benit P, Slama A, Cartault F, et al. Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet 2004;41:14–17.
78. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67:360–368.
79. Chretien D, Bénit P, Chol M, et al. Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochem Biophys Res Commun 2003;301:222–224.
80. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J Biol Chem 2012;287:27255–27264.
81. Ganesh J, Wong L-JC, Gorman EB. Mitochondrial respiratory chain complex II. In: Wong L-JC, editor. Mitochondrial disorders caused by nuclear genes. New York: Springer, 2013;203–218.
82. Dröse S. Differential effects of complex II on mitochondrial ROS production and their relation to cardioprotective pre- and postconditioning. Biochim Biophys Acta 2013;1827:578–587.
83. Haut S, Brivet M, Touati G, et al. A deletion in the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic acidosis. Hum Genet 2003;113:118–122.
84. Borisov VB. Defects in mitochondrial respiratory complexes III and IV, and human pathologies. Mol Aspects Med 2002;23:385–412.
85. Diaz F, Fukui H, Garcia S, Moraes CT. Cytochrome c oxidase is required for the assembly/stability of respiratory complex I in mouse fibroblasts. Mol Cell Biol 2006;26:4872–4881.
86. Li X, Yang Y. Mitochondrial disorders associated with mitochondrial respiratory chain complex V deficiency. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:596–600.
87. Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: Architecture, function and pathology. J Inherit Metab Dis 2012;35:211–225.
88. Valerio A, Bertolotti P, Delbarba A, et al. Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 2011;116:1148–1159.
89. Golpich M, Rahmani B, Ibrahim NM, et al. Preconditioning as a potential strategy for the prevention of Parkinson's disease. Mol Neurobiol 2015;51:313–330.
90. Rosenstock TR, Rego AC. Modified mitochondrial dynamics, turnover and function in neurodegeneration: A focus on Huntington's Disease. In: Lou P-H, Petersen N, editors. Cell Bioener Health Dis: New Perspectives in Mitochondrial Biology. Kerala: Research Signpost; 2012;149–194.
91. Zhang Q, Wu Y, Zhang P, et al. Exercise induces mitochondrial biogenesis after brain ischemia in rats. Neuroscience 2012;205:10–17.
92. Uittenbogaard M, Chiaramello A. Mitochondrial biogenesis: A therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des 2014;20:5574–5593.
93. Dominy JE, Puigserver P. Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harbor Perspect Biol 2013;5:1–18.
94. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008;88:611–638.
95. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 2010;106:1681–U46.
96. Vercauteren K, Pasko RA, Gleyzer N, Marino VM, Scarpulla RC. PGC-1-related coactivator: Immediate early expression and characterization of a CREB/NRF-1 binding domain associated with cytochrome c promoter occupancy and respiratory growth. Mol Cell Biol 2006;26:7409–7419.
97. Wu ZD, Huang XM, Feng YJ, et al. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1 alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci U S A 2006;103:14379–14384.
98. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 2011;1813:1269–1278.
99. Yin W, Signore AP, Iwai M, Cao GD, Gao YQ, Chen J. Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury. Stroke 2008;39:3057–3063.
100. Chen YC, Wu JS, Tsai HD, et al. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol Neurobiol 2012;46:114–124.
101. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD(+) metabolism and SIRT1 activity. Nature 2009;458:1056–U140.
102. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev 2009;89:1025–1078.
103. Hardie DG. The AMP-activated protein kinase pathway – new players upstream and downstream. J Cell Sci 2004;117:5479–5487.
104. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 2012;342:619–630.
105. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006;574:33–39.
106. Lee H-L, Chen C-L, Yeh ST, Zweier JL, Chen Y-R. Biphasic modulation of the mitochondrial electron transport chain in myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2012;302:H1410–H1422.
107. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151–3171.
108. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004;29:32–38.
109. Piantadosi CA, Suliman HB. Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. J Biol Chem 2006;281:324–333.
110. Min S-W, Sohn PD, Cho S-H, Swanson RA, Gan L. Sirtuins in neurodegenerative diseases: An update on potential mechanisms. Front Aging Neurosci 2013;5:1–9.
111. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 2013;23:746–758.
112. Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012;483:218–221.
113. Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010;5:e11707.
114. Schreiber SN, Emter R, Hock MB, et al. The estrogen-related receptor alpha (ERR alpha) functions in PPAR gamma coactivator 1 alpha (PGC-1 alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci U S A 2004;101:6472–6477.
115. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006;27:728–735.
116. Madrazo JA, Kelly DP. The PPAR trio: Regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008;44:968–975.
117. Andersen G, Wegner L, Yanagisawa K, et al. Evidence of an association between genetic variation of the coactivator PGC-1 beta and obesity. J Med Genet 2005;42:402–407.
118. Dang CV, Li F, Lee LA. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle 2005;4:1465–1466.
119. Ramachandran B, Yu GS, Gulick T. Nuclear respiratory factor 1 controls myocyte enhancer factor 2A transcription to provide a mechanism for coordinate expression of respiratory chain subunits. J Biol Chem 2008;283:11935–11946.
120. Rocha M, Hernandez-Mijares A, Garcia-Malpartida K, Bañuls C, Bellod L, M Victor V. Mitochondria-targeted antioxidant peptides. Curr Pharm Des 2010;16:3124–3131.
121. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014;171:2029–2050.
122. Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2006;98:1141–1148.
123. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007;47:629–656.
124. Cochemé HM, Kelso GF, James AM, et al. Mitochondrial targeting of quinones: Therapeutic implications. Mitochondrion 2007;7:S94–S102.
125. Dumont M, Kipiani K, Yu F, et al. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2011;27:211–223.
126. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes. Biochim Biophys Acta 2014;1842:1282–1294.
127. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009;109:1427–1439.
128. Miquel E, Cassina A, Martínez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med 2014;70:204–213.
129. Hou Y, Li S, Wu M, et al. Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. Am J Physiol Renal Physiol 2016;310:F547–F559.
130. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 2007;282:4634–4642.
131. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. Drug addiction. New York: Springer, 2008;535–546.
132. Manczak M, Mao P, Calkins MJ, et al. Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010;20(S2):609–631.
133. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 2009;11:2095–2104.
134. Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord 2014;29:285–293.
135. Nussbaum JM, Schilling S, Cynis H, et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012;485:651–655.
136. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674–678.
137. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012;482:216–U107.
138. Dragicevic N, Mamcarz M, Zhu YY, et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in alzheimer's transgenic mice. J Alzheimers Dis 2010;20:S535–S550.
139. Zhang H, Jia H, Liu J, et al. Combined R-α–lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med 2010;14:215–225.
140. Marongiu R, Spencer B, Crews L, et al. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem 2009;108:1561–1574.
141. Eckert A, Nisbet R, Grimm A, Götz J. March separate, strike together—Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 2014;1842:1258–1266.
142. Hroudová J, Singh N, Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer's disease. BioMed Res Int 2014;2014:1–9.
143. Zhang L, Zhang S, Maezawa I, et al. Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's disease. EBioMedicine 2015;2:294–305.
144. Kruger J, Hinttala R, Majamaa K, Remes AM. Mitochondrial DNA haplogroups in early-onset Alzheimer's disease and frontotemporal lobar degeneration. Mol Neurodegener 2010;5:6.
145. Manczak M, Jung YS, Park BS, Partovi D, Reddy PH. Time-course of mitochondrial gene expressions in mice brains: Implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 2005;92:494–504.
146. Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy in posterior cingulate metabolism genes neurons. Proc Natl Acad Sci U S A 2008;105:4441–4446.
147. Diana A, Simic G, Sinforiani E, Orru N, Pichiri G, Bono G. Mitochondria morphology and DNA content upon sublethal exposure to beta-amyloid(1-42) peptide. Coll Anthropol 2008;32:51–58.
148. Puranam KL, Wu GH, Strittmatter WJ, Burke JR. Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem Biophys Res Commun 2006;341:607–613.
149. Liu Z, Li P, Wu J, et al. The cascade of oxidative stress and tau protein autophagic dysfunction in Alzheimer's disease. In: Zerr I, editor. Alzheimer's Disease - Challenges for the Future. Rijeka: Intech, 2015.
150. Zhang Q, Yu JT, Wang P, et al. Mitochondrial transcription factor A (TFAM) polymorphisms and risk of late-onset Alzheimer's disease in Han Chinese. Brain Res 2011;1368:355–360.
151. Blacker D, Bertram L, Saunders AJ, et al. Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Hum Mol Genet 2003;12:23–32.
152. Gunther C, von Hadeln K, Muller-Thomsen T, et al. Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neurosci Lett 2004;369:219–223.
153. d'Abramo C, Ricciarelli R, Pronzato MA, Davies P. Troglitazone, a peroxisome proliferator-activated receptor-γ agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 2006;98:1068–1077.
154. Du L-L, Chai D-M, Zhao L-N, et al. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. J Alzheimers Dis 2015;43:775–784.
155. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169–3179.
156. Tomiyama H, Mizuta I, Li Y, et al. LRRK2 P755L variant in sporadic Parkinson's disease. J Hum Genet 2008;53:1012–1015.
157. Tomas-Camardiel M, Rite I, Herrera AJ, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004;16:190–201.
158. Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment. Restor Neurol Neurosci 2013;31:155–167.
159. Greenamyre JT, Hastings TG. Parkinson's: Divergent causes, convergent mechanisms. Science 2004;304:1120–1122.
160. Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C. Life span and locomotor activity modification by glucose and polyphenols in Drosophila melanogaster chronically exposed to oxidative stress-stimuli: Implications in Parkinson's disease. Neurochem Res 2011;36:1073–1086.
161. Weise J, Engelhorn T, Dörfler A, Aker S, Bähr M, Hufnagel A. Expression time course and spatial distribution of activated caspase-3 after experimental status epilepticus: Contribution of delayed neuronal cell death to seizure-induced neuronal injury. Neurobiol Dis 2005;18:582–590.
162. Ng C-H, Guan MS, Koh C, et al. AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J Neurosci 2012;32:14311–14317.
163. Choi HJ, Lee SY, Cho Y, No H, Kim SW, Hwang O. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease. Neurochem Int 2006;48:255–262.
164. Keeney PM, Xie J, Capaldi RA, Bennett JP. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006;26:5256–5264.
165. Tobon-Velasco JC, Limon-Pacheco JH, Orozco-Ibarra M, et al. 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappa B factors. Toxicology 2013;304:109–119.
166. Cho D-H, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 2010;67:3435–3447.
167. Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207–219.
168. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002;22:7006–7015.
169. Shamoto-Nagai M, Maruyama W, Kato Y, et al. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 2003;74:589–597.
170. Nakamura T, Cho DH, Lipton SA. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol 2012;238:12–21.
171. Thomas RR, Keeney PM, Bennett JP. Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. J Parkinsons Dis 2012;2:67–76.
172. Schon EA, Przedborski S. Mitochondria: The next (Neurode)generation. Neuron 2011;70:1033–1053.
173. Zhu JH, Gusdon AM, Cimen H, Van Houten B, Koc E, Chu CT. Impaired mitochondrial biogenesis contributes to depletion of functional mitochondria in chronic MPP+ toxicity: Dual roles for ERK1/2. Cell Death Dis 2012;3:10.
174. Zheng B, Liao ZX, Locascio JJ, et al. PGC-1 alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:14.
175. Chu CT. A pivotal role for PINK1 and autophagy in mitochondrial quality control: Implications for Parkinson disease. Hum Mol Genet 2010;19:R28–R37.
176. Schmidt S, Linnartz B, Mendritzki S, et al. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum Mol Genet 2011;20:1197–1211.
177. Kuroda Y, Mitsui T, Kunishige M, et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006;15:883–895.
178. Pilsl A, Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: Emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol 2012;123:173–188.
179. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. EMBO J 2012;31:3038–3062.
180. Dagda RK, Pien I, Wang R, et al. Beyond the mitochondrion: Cytosolic PINK1 remodels dendrites through Protein Kinase A. J Neurochem 2014;128:864–877.
181. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010;8:e1000298.
182. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ. PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 2013;200:163–172.
183. Gegg ME, Cooper JM, Schapira AH, Taanman J-W. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 2009;4:e4756.
184. Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radic Biol Med 2015;88:179–188.
185. Lin T-K, Liou C-W, Chen S-D, et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med J 2009;32:589–599.
186. Gaweda-Walerych K, Safranow K, Maruszak A, et al. Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett 2010;469:24–29.
187. Keeney PM, Quigley CK, Dunham LD, et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 2009;20:897–907.
188. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615–624.
189. Heneka MT, Landreth GE, Hull M. Drug Insight: Effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 2007;3:496–504.
190. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPAR gamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol 2012;235:528–538.
191. Hang L, Basil AH, Lim K-L. Nutraceuticals in Parkinson's Disease. NeuroMol Med 2016;18:306–321.
192. Donmez G, Arun A, Chung C-Y, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci 2012;32:124–132.
193. Bennett EJ, Shaler TA, Woodman B, et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007;448:704–708.
194. Yang SH, Cheng PH, Banta H, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008;453:921–U56.
195. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant Huntingtin-expressing cells possible role of peroxisome proliferator-activated receptor-γ (PPARγ) in the pathogenesis of Huntington disease. J Biol Chem 2008;283:25628–25637.
196. Chiang M-C, Chern Y, Juo C-G. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. Biochim Biophys Acta 2011;1812:1111–1120.
197. Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet 2010;19:3190–3205.
198. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1α function in muscle in Huntington's disease. Hum Mol Genet 2009;18:3048–3065.
199. Phan J, Hickey MA, Zhang PX, Chesselet MF, Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 2009;18:1006–1016.
200. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab 2006;4:349–362.
201. Chiang M-C, Chern Y, Huang R-N. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. Neurobiol Dis 2012;45:322–328.
202. Reddy PH, Mao P, Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev 2009;61:33–48.
203. Pandey M, Varghese M, Sindhu KM, et al. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J Neurochem 2008;104:420–434.
204. Kim J, Moody JP, Edgerly CK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet 2010;19:3919–3935.
205. Benit P, Lebon S, Rustin P. Respiratory-chain diseases related to complex III deficiency. Biochim Biophys Acta 2009;1793:181–185.
206. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 2008;9:505–518.
207. Johri A, Chandra A, Beal MF. PGC-1 alpha, mitochondrial dysfunction, and Huntington's disease. Free Radic Biol Med 2013;62:37–46.
208. Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 2012;21:1124–1137.
209. Tsunemi T, Ashe TD, Morrison BE, et al. PGC-1 alpha rescues huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 2012;4:142–197.
210. Bastin J, Aubey F, Rotig A, Munnich A, Djouadi F. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients’ cells lacking its components. J Clin Endocrinol Metab 2008;93:1433–1441.
211. Wenz TN, Wang X, Marini M, Moraes CT. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2011;15:2317–2325.
212. Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2012;18:153–158.
213. Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 2002;83:535–545.
214. Duffy LM, Chapman AL, Shaw PJ, Grierson AJ. Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2011;37:336–352.
215. Lee J, Kannagi M, Ferrante RJ, Kowall NW, Ryu H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB J 2009;23:1739–1749.
216. Benedusi V, Martorana F, Brambilla L, Maggi A, Rossi D. The Peroxisome Proliferator-Activated Receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in Amyotrophic Lateral Sclerosis. J Biol Chem 2012;287:35899–35911.
217. Perera ND, Sheean RK, Scott JW, Kemp BE, Horne MK, Turner BJ. Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS One 2014;9:e90449.